These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34567270)

  • 1. Primary care and referring physician perspectives on non-alcoholic fatty liver disease management: a nationwide survey.
    Saeed N; Glass LM; Habbal H; Mahmood A; Sengstock D; Saini SD; Tincopa MA
    Therap Adv Gastroenterol; 2021; 14():17562848211042200. PubMed ID: 34567270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us?
    Wessels DH; Rosenberg Z
    World J Hepatol; 2021 Feb; 13(2):233-241. PubMed ID: 33708352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underappreciation of non-alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis.
    Patel PJ; Banh X; Horsfall LU; Hayward KL; Hossain F; Johnson T; Stuart KA; Brown NN; Saad N; Clouston A; Irvine KM; Russell AW; Valery PC; Williams S; Powell EE
    Intern Med J; 2018 Feb; 48(2):144-151. PubMed ID: 29083080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and severity of non-alcoholic fatty liver disease are underestimated in clinical practice: impact of a dedicated screening approach at a large university teaching hospital.
    Marjot T; Sbardella E; Moolla A; Hazlehurst JM; Tan GD; Ainsworth M; Cobbold JFL; Tomlinson JW
    Diabet Med; 2018 Jan; 35(1):89-98. PubMed ID: 29094442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
    Blond E; Disse E; Cuerq C; Drai J; Valette PJ; Laville M; Thivolet C; Simon C; Caussy C
    Diabetologia; 2017 Jul; 60(7):1218-1222. PubMed ID: 28352941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of a community-based diagnostic pathway to stratify adults for non-alcoholic fatty liver disease: a Markov model informed by a feasibility study.
    Tanajewski L; Harris R; Harman DJ; Aithal GP; Card TR; Gkountouras G; Berdunov V; Guha IN; Elliott RA
    BMJ Open; 2017 Jul; 7(6):e015659. PubMed ID: 28679676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Awareness of nonalcoholic steatohepatitis and associated practice patterns of primary care physicians and specialists.
    Polanco-Briceno S; Glass D; Stuntz M; Caze A
    BMC Res Notes; 2016 Mar; 9():157. PubMed ID: 26969270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?
    Sanyal AJ
    BMC Med; 2018 Aug; 16(1):148. PubMed ID: 30139362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient elastography for screening of liver fibrosis: Cost-effectiveness analysis from six prospective cohorts in Europe and Asia.
    Serra-Burriel M; Graupera I; Torán P; Thiele M; Roulot D; Wai-Sun Wong V; Neil Guha I; Fabrellas N; Arslanow A; Expósito C; Hernández R; Lai-Hung Wong G; Harman D; Darwish Murad S; Krag A; Pera G; Angeli P; Galle P; Aithal GP; Caballeria L; Castera L; Ginès P; Lammert F;
    J Hepatol; 2019 Dec; 71(6):1141-1151. PubMed ID: 31470067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification, evaluation, and management of obesity in an academic primary care center.
    O'Brien SH; Holubkov R; Reis EC
    Pediatrics; 2004 Aug; 114(2):e154-9. PubMed ID: 15286251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe.
    Lazarus JV; Ekstedt M; Marchesini G; Mullen J; Novak K; Pericàs JM; Roel E; Romero-Gómez M; Ratziu V; Tacke F; Cortez-Pinto H; Anstee QM;
    J Hepatol; 2020 Jan; 72(1):14-24. PubMed ID: 31518646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score.
    Tapper EB; Hunink MG; Afdhal NH; Lai M; Sengupta N
    PLoS One; 2016; 11(2):e0147237. PubMed ID: 26905872
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care.
    Hofmann WP; Buggisch P; Schubert L; Dikopoulos N; Schwenzer J; Muche M; Felten G; Heyne R; Ingiliz P; Schmidt A; Stein K; Wedemeyer H; Berg T; Wiegand J; Lammert F; Zeuzem S; Schattenberg JM
    JHEP Rep; 2020 Dec; 2(6):100168. PubMed ID: 32964201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis of liver fibrosis in ageing patients with HIV at risk for non-alcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway.
    Sebastiani G; Milic J; Gioe C; Al Hinai AS; Cervo A; Lebouche B; Deschenes M; Cascio A; Mazzola G; Guaraldi G
    Lancet HIV; 2022 Mar; 9 Suppl 1():S4. PubMed ID: 35304846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fighting liver fat.
    Koeckerling D; Tomlinson JW; Cobbold JF
    Endocr Connect; 2020 Jul; 9(7):R173-R186. PubMed ID: 32621584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough.
    Castera L
    Liver Int; 2018 Feb; 38 Suppl 1():67-70. PubMed ID: 29427494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Embedding assessment of liver fibrosis into routine diabetic review in primary care.
    Mansour D; Grapes A; Herscovitz M; Cassidy P; Vernazza J; Broad A; Anstee QM; McPherson S
    JHEP Rep; 2021 Aug; 3(4):100293. PubMed ID: 34179738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for undiagnosed non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): A population-based risk factor assessment using vibration controlled transient elastography (VCTE).
    Eskridge W; Vierling JM; Gosbee W; Wan GA; Hyunh ML; Chang HE
    PLoS One; 2021; 16(11):e0260320. PubMed ID: 34847156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease and the interface between primary and secondary care.
    Tsochatzis EA; Newsome PN
    Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):509-517. PubMed ID: 29893235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography.
    Lai LL; Wan Yusoff WNI; Vethakkan SR; Nik Mustapha NR; Mahadeva S; Chan WK
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1396-1403. PubMed ID: 30551263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.